Research Summaries

In the Future, Patients with a Rare Neoplastic Joint Disease May Have a New Treatment Option

ASCO Annual Meeting
May 14, 2014

Early-stage research suggests that a new targeted drug, PLX3397, could become a treatment option for people with a neoplastic joint disorder called pigmented villonodular synovitis (PVNS). PVNS is a rare joint condition that usually affects the hip or knee, causing tumors to form in these joints that destroy joint tissue and cause severe, life-changing symptoms. PVNS is a type of uncontrollable cell growth, similar to a cancer, but it is not considered a cancer because it usually does not spread to other parts of the body.

Pages

Subscribe to RSS - Research Summaries